Hospital Clinic de Barcelona. Unidad de Nuevas Terapias;Oncology Department

Barcelona 08036

0 studies enrolling now · 2 studies all time

What they study most

Carcinoma, Transitional Cell, Renal Cell Carcinoma

Studies at this site

• A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection — Stopped early
• A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma — Completed